The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and pharmaceutical industries, shifting responsibility for drug costs away from beneficiaries and onto plans and manufacturers. The law affects provider reimbursement, changes AMP and ASP calculations, and, perhaps most significantly, allows the federal government to negotiate prices for the first time—all of which present challenges to even the most experienced companies. Join our experts as we break down the Inflation Reduction Act, including how it will be implemented and who is most affected.
Learning objectives:
- Major IRA provisions and timeline for implementation
- Drugs selected for the Drug Price Negotiation Program and implementation by managed care
- Implications for pharma manufacturers